FLT1 and hepatocellular carcinoma: In clinical studies, vatalanib, which inhibits VEGFR-1 and -2, PDGFR and c-Kit, has been shown to suppress hepatocellular carcinoma (HCC) growth and to have anti-neoplastic effects in other solid tumors [51, 52].